Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

Other Disorders of Digestive System

Other Disorders of Digestive System

The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

COVID-19 pandemic and lockdown stress consequences in people with and without Irritable Bowel Syndrome.

Ethics, medicine, and public health·2021

Same author

Long-term endoscopic follow-up after sleeve gastrectomy.

Journal of visceral surgery·2020

Same author

Trace element contamination in fish impacted by bauxite red mud disposal in the Cassidaigne canyon (NW French Mediterranean).

The Science of the total environment·2019

Same author

Growth, condition and metal concentration in juveniles of two Diplodus species in ports.

Marine pollution bulletin·2018

Same author

Is-it possible to distinguish irritable bowel syndrome with constipation from functional constipation?

Techniques in coloproctology·2017

Same author

Faecal contamination of echinoderms: first report of heavy Escherichia coli loading of sea urchins from a natural growing area.

Letters in applied microbiology·2015

Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026

Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026

Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026

Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026

Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026

Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Metformin and digestive disorders.

M Bouchoucha¹, B Uzzan, R Cohen

¹Service de gastroentérologie, hôpital Avicenne, AP-HP, université Paris-V René-Descartes, 125, route de Stalingrad, 93009 Bobigny, France.

Diabetes & Metabolism

|January 18, 2011

Summary

This summary is machine-generated.

Metformin, a common type 2 diabetes drug, causes digestive issues like diarrhea and vomiting in about 30% of patients. Current theories don't fully explain these common metformin side effects.

More Related Videos

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Area of Science:

Gastroenterology
Pharmacology
Endocrinology

Background:

Digestive disorders, including diarrhea and vomiting, are the most frequent adverse effects of metformin, affecting approximately 30% of patients using this first-line type 2 diabetes medication.
Metformin influences glucose, vitamin B12, and bile salt absorption in the digestive tract, with local effects on glucose metabolism in the colon.

Purpose of the Study:

To review and critically evaluate the proposed pathophysiological hypotheses for metformin-induced digestive side effects.
To highlight the lack of experimental data supporting current theories and the patient-dependent nature of these adverse effects.

Main Methods:

Literature review of proposed pathophysiological mechanisms for metformin-induced gastrointestinal symptoms.
Analysis of existing hypotheses including serotonin secretion, incretin and glucose metabolism, and bile salt malabsorption.

Main Results:

Several hypotheses exist for metformin's digestive side effects, such as altered serotonin, incretin, and glucose metabolism, or bile salt malabsorption.
None of the proposed hypotheses adequately explain the observed gastrointestinal adverse effects of metformin.
There is a significant lack of experimental data to elucidate the mechanisms behind these patient-specific side effects.

Conclusions:

The exact pathophysiological mechanisms underlying metformin-induced diarrhea and vomiting remain unclear.
Further experimental research is needed to understand the patient-dependent adverse effects of metformin on the digestive system.